Overview Trial of IMO-8400 in Adult Patients With Dermatomyositis Status: Completed Trial end date: 2018-06-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis. Phase: Phase 2 Details Lead Sponsor: Idera Pharmaceuticals, Inc.